<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722072</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00004318</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-4318</secondary_id>
    <secondary_id>BAYER-OHSU-4318</secondary_id>
    <secondary_id>CDR0000601002</secondary_id>
    <nct_id>NCT00722072</nct_id>
  </id_info>
  <brief_title>Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy</brief_title>
  <official_title>A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth&#xD;
      of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking&#xD;
      the use of estrogen by the tumor cells. Giving sorafenib together with fulvestrant may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving sorafenib together with fulvestrant&#xD;
      works in treating patients with locally advanced or metastatic breast cancer that did not&#xD;
      respond to aromatase inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To investigate the clinical activity of sorafenib tosylate and fulvestrant, as&#xD;
           determined by a 4-month progression-free survival rate, in patients with hormone&#xD;
           receptor-positive locally advanced or metastatic breast cancer that progressed after&#xD;
           prior treatment with an aromatase inhibitor.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the objective response rate in patients treated with this regimen.&#xD;
&#xD;
        -  To determine the median time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  To determine the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  To determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  To establish the safety and tolerability profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral sorafenib tosylate twice daily on days 1-28. Patients also&#xD;
      receive fulvestrant intramuscularly on days 1 and 15 of course 1 and on day 1 of all&#xD;
      subsequent courses. Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 28-56 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor pulled funding and low accrual&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Progression-free Survival at 4 Months</measure>
    <time_frame>4 months after initiating treatment with sorafenib plus fulvestrant.</time_frame>
    <description>Progression-free survival rate is defined as the proportion of subjects who are progression free (CR, PR and SD) at 4 months after initiating treatment with sorafenib plus fulvestrant. Complete Response (CR):Disappearance of all target (both measurable and evaluable)lesions. Partial Response (PR):At least a 30% decrease in the sum of the longest diameter (LD) of both measurable and evaluable target lesions. Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease(PD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Every 8 weeks (two cycles) while receiving study therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Start of treatment to time of progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Start of treatment to time of progression or death, whichever comes first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>28 to 56 days after discontinuation of study therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Fulvestrant/ Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.&#xD;
Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy</description>
    <arm_group_label>Fulvestrant/ Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy</description>
    <arm_group_label>Fulvestrant/ Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of incurable breast cancer&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease is defined as ≥ 1 uni-dimensionally measurable lesion ≥ 20 mm&#xD;
                  by conventional techniques or ≥ 10 mm by spiral computed tomography(CT) scan&#xD;
&#xD;
                    -  Bone-only metastases that can be imaged with bone scan AND magnetic&#xD;
                       resonance imaging (MRI) or bone scan AND plain x-ray is considered&#xD;
                       measurable disease&#xD;
&#xD;
                    -  Tumor lesions that are situated in a previously irradiated area are&#xD;
                       considered measurable only if they are progressing at the time of study&#xD;
                       entry&#xD;
&#xD;
               -  Evaluable disease includes unresectable skin/chest wall metastases that can be&#xD;
                  photographed and whose size can be measured with a ruler&#xD;
&#xD;
                    -  Bone-only metastases that can only be imaged using bone scan or malignant&#xD;
                       pleural effusion(s) only are not considered evaluable disease&#xD;
&#xD;
          -  Previously treated with a third-generation aromatase inhibitor (e.g., letrozole,&#xD;
             anastrazole, or exemestane) AND meets one of the following criteria:&#xD;
&#xD;
               -  Progressed during palliative aromatase inhibitor therapy&#xD;
&#xD;
               -  Recurred during adjuvant aromatase inhibitor therapy&#xD;
&#xD;
               -  Recurred within 12 months of completing adjuvant aromatase inhibitor therapy&#xD;
&#xD;
          -  Human Epidermal growth factor Receptor 2(HER2/neu)-negative tumor&#xD;
&#xD;
               -  No Human Epidermal growth factor Receptor 2(HER2/neu) overexpression (i.e., tumor&#xD;
                  staining 3+ by immunohistochemistry [IHC] or gene amplified by Fluorescence In&#xD;
                  Situ Hybridization [FISH])&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor and/or progesterone receptor positive, defined as ≥ 10% of&#xD;
                  malignant cells with positive nuclear staining&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  Eastern Cooperative Group(ECOG) performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 16 weeks&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase(AST) ≤ 2.5 times ULN (≤&#xD;
             5 times ULN for patients with liver involvement)&#xD;
&#xD;
          -  International Normalized Ratio(INR) &lt; 1.5 OR Prothrombin time/ partial thromboplastin&#xD;
             time (PT/PTT) normal&#xD;
&#xD;
          -  Left ventricular ejection fraction(LVEF) normal by Multiple Gated Acquisition(MUGA) or&#xD;
             ECHO&#xD;
&#xD;
          -  No known allergy to sorafenib tosylate or fulvestrant&#xD;
&#xD;
          -  No cardiac disease, including any of the following:&#xD;
&#xD;
               -  New York Heart Association(NYHA) class III-IV congestive heart failure&#xD;
&#xD;
               -  Unstable angina (anginal symptoms at rest) or new-onset angina (within the past 3&#xD;
                  months)&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
          -  No uncontrolled hypertension, defined as systolic blood pressure &gt; 150 mm Hg or&#xD;
             diastolic blood pressure &gt; 90 mm Hg despite optimal medical management&#xD;
&#xD;
          -  No thrombotic or embolic events, such as cerebrovascular accident (including transient&#xD;
             ischemic attacks), within the past 6 months&#xD;
&#xD;
          -  No known HIV infection or chronic hepatitis B or C infection&#xD;
&#xD;
          -  No infection that requires IV antibiotics or produces a fever &gt; 100°F within the past&#xD;
             72 hours&#xD;
&#xD;
          -  No pulmonary hemorrhage/bleeding event ≥ Common terminology criteria for adverse&#xD;
             events(CTCAE) grade 2 within the past 4 weeks&#xD;
&#xD;
          -  No other hemorrhage/bleeding event ≥ CTCAE grade 3 within the past 4 weeks&#xD;
&#xD;
          -  No evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No significant traumatic injury within the past 2 weeks&#xD;
&#xD;
          -  No serious, nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No condition that impairs the patient's ability to swallow whole pills&#xD;
&#xD;
          -  No malabsorption problem&#xD;
&#xD;
          -  No second malignancy within the past 5 years, except adequately treated and cured&#xD;
             basal cell or squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No underlying medical condition that, in the principal investigator's opinion, will&#xD;
             make the administration of study drug hazardous or would obscure the interpretation of&#xD;
             adverse events&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy for metastatic or unresectable locally advanced breast cancer&#xD;
&#xD;
          -  No prior sorafenib tosylate or other Vascular endothelial growth&#xD;
             factor(VEGF)-targeting therapies&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery or open biopsy&#xD;
&#xD;
          -  No concurrent anticoagulation with warfarin or heparin&#xD;
&#xD;
          -  No concurrent Hypericum perforatum (St. John wort) or rifampin&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy or biological therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Chui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <results_first_submitted>August 4, 2011</results_first_submitted>
  <results_first_submitted_qc>August 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2011</results_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib and Fulvestrant</title>
          <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib and Fulvestrant</title>
          <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.166" spread="9.0235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progression-free Survival at 4 Months</title>
        <description>Progression-free survival rate is defined as the proportion of subjects who are progression free (CR, PR and SD) at 4 months after initiating treatment with sorafenib plus fulvestrant. Complete Response (CR):Disappearance of all target (both measurable and evaluable)lesions. Partial Response (PR):At least a 30% decrease in the sum of the longest diameter (LD) of both measurable and evaluable target lesions. Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease(PD).</description>
        <time_frame>4 months after initiating treatment with sorafenib plus fulvestrant.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Fulvestrant</title>
            <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression-free Survival at 4 Months</title>
          <description>Progression-free survival rate is defined as the proportion of subjects who are progression free (CR, PR and SD) at 4 months after initiating treatment with sorafenib plus fulvestrant. Complete Response (CR):Disappearance of all target (both measurable and evaluable)lesions. Partial Response (PR):At least a 30% decrease in the sum of the longest diameter (LD) of both measurable and evaluable target lesions. Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease(PD).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <time_frame>Every 8 weeks (two cycles) while receiving study therapy.</time_frame>
        <population>Response assessment data was not collected past 4 months due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Fulvestrant</title>
            <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <population>Response assessment data was not collected past 4 months due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <time_frame>Start of treatment to time of progression.</time_frame>
        <population>Progression data was not collected due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Fulvestrant</title>
            <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <population>Progression data was not collected due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Start of treatment to time of progression or death, whichever comes first.</time_frame>
        <population>Long term survival data was not collected due to early study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Fulvestrant</title>
            <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Long term survival data was not collected due to early study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>28 to 56 days after discontinuation of study therapy</time_frame>
        <population>Long term survival data was not collected due to early study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Fulvestrant</title>
            <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Long term survival data was not collected due to early study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib and Fulvestrant</title>
          <description>Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:&#xD;
500 mg IM on Day 1&#xD;
250 mg IM on Day 15&#xD;
Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot syndrome (HFS)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthralgias</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgias</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen Chui</name_or_title>
      <organization>OHSU Knight Cancer Institute</organization>
      <phone>503-494-8534</phone>
      <email>chuis@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

